CD274 and non-small cell lung carcinoma: Among 1,177 patients with completely resected, PD-L1-positive, stage IB to IIIA NSCLC (as per the 7th edition of the AJCC staging system), adjuvant pembrolizumab improved disease-free survival compared to placebo (54 vs. 42 months; hazard ratio, 0.76; 95% CI, 0.63–0.91; P = 0.001), with a nonsignificant trend towards improvement in those with tumor expression of PD-L1 of 50% or more (median disease-free survival not reached in either arm; hazard ratio, 0.82; 95% CI, 0.57–1.18; P = 0.140).